Novartis stock holds firm after Entresto patent win
Published on 08/14/2026 at 16:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis AG (CH0012005267) stock drew a fresh focus on August 13, 2026, after a UK court challenge tied to Entresto patents turned into a supportive legal read-through for the company. The shares closed at CHF 123.74 in Zurich on August 13, 2026, with a 1-day move of -0.37% and a 1st Jan gain of +12.90%.
Patent news and market read
Market data showed a market value of 289 billion and a 52-week range of CHF 107.68 to CHF 131.50, placing the stock inside the upper half of its yearly band. The same quote snapshot also showed a 5-day move of -1.15%, which frames the legal headline as a one-session event rather than a change in the longer trend.
The legal development matters because Entresto remains one of Novartis' best-known cardiovascular brands, and the news flow around the patent has been strong enough to keep the stock visible in Swiss trading coverage. That backdrop is reinforced by a market consensus of HOLD and an average target price of $154.18, both of which suggest a measured stance rather than a high-conviction rerating.
Q2 2026 still anchors the numbers
Novartis' latest earnings snapshot, for Q2 2026, showed revenue of $14.95 billion and earnings per share of $2.41. Those figures matter because they are the most recent reported fundamentals in this cycle and they provide the base for current valuation debate.
The comparison is straightforward: the quarter delivered $14.95 billion in sales and $2.41 in EPS, while analysts are looking for 8.85 EPS for the full 2026 fiscal year. That gap shows why the market is still weighing execution, patent durability, and pipeline progress together rather than pricing the stock on one headline alone.
Balance-sheet and profitability data from the same earnings snapshot also remained solid, with return on equity of 38.56% and net margin of 23.29%. For investors, those numbers matter more than a single day of legal noise because they show the underlying earnings power that supports the shares.
Pipeline and protection
Novartis is still leaning on a broad portfolio that spans oncology, immunology, cardiovascular and metabolic diseases, neuroscience, and ophthalmology. In the company profile, oncology accounted for 30.9% of net sales, immunology for 18.9%, and cardiovascular, renal and metabolic diseases for 16.4%.
The representative product most tied to the current debate is Entresto, the heart-failure treatment at the center of the UK patent challenge. That keeps the legal story connected to a commercial franchise that remains strategically important inside the wider Novartis mix.
Shares and setup
Novartis stock ended the last Swiss session at CHF 123.74, with a year-to-date rise of 12.90% and a 52-week high of CHF 131.50. The combination of a legal win, a CHF 289 billion market value, and Q2 2026 sales of $14.95 billion gives the shares a clear near-term framework going into the next trading stretch.
More on Novartis stock
Company: Novartis AG
ISIN: CH0012005267
Ticker: NOVN
Exchange: Swiss Exchange
Market cap: 289 billion
Sector / Industry: Pharmaceuticals
Index membership: Swiss Market Index
